Quantcast

DrugRisk Update: New Study Adds to Yaz Blood Clot Risks as Settlements Continue

January 18, 2013

The DrugRisk Resource Center is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

Dallas, TX (PRWEB) January 18, 2013

The prescription drug resource center DrugRisk.com is alerting women taking the birth control drugs Yaz or Yasmin of a new study added to the site showing blood clot risks may be higher with these contraceptives. Also, those suffering from migraines may have a heightened risk.

“The goal of DrugRisk is to improve patient safety through education. This includes the latest medication studies, recalls, and litigation news. Although recent studies have linked Yaz to blood clots, this is the first we´ve seen that specifically addresses women suffering from migraines,” explains DrugRisk representative Ryan Mayer.

DrugRisk recently added information from the American College of Obstetricians and Gynecologists, who became the latest group to warn that birth control pills containing drospirenone, like Yaz and Yasmin, may cause higher risks of blood clots.* France´s Health Ministry has also said they will stop reimbursements for the drugs over similar concerns.**

Now, a new study from Brigham and Women´s Faulkner Hospital in Boston added to the resource center found that, while combined hormone contraceptives like Yaz and Yasmin may raise blood clot risks for all women, the risks are significantly higher for those suffering migraines.***

DrugRisk has learned that thousands of patients in the U.S. have filed a Yaz lawsuit over blood clots. These have been consolidated to a special Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

Bayer´s latest financial statements show they have spent almost $750 million to settle around 3,500 Yaz lawsuits for blood clot injuries at an average of or around $214,000 per case.**** The company has also set aside more funds for additional claims.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options. While there has been no Yaz recall, the drug has been linked to serious side effects.

DrugRisk cautions victims who wish to learn about their legal options that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”

** reuters.com/article/2013/01/03/france-contraception-idUSL5E9C31XG20130103

***foxnews.com/health/2013/01/15/migraines-with-aura-linked-to-heart-disease/

****Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebyaz-recall/information/prweb10336632.htm


Source: prweb



comments powered by Disqus